BioKnow

𝗣𝗵𝗮𝗿𝗺𝗮'𝘀 𝟱-𝗬𝗲𝗮𝗿 𝗠&𝗔 𝗗𝗲𝗮𝗹𝘀: Big Bets Made Since 2019 👇 🥁 Pfizer, AbbVie, and BMS make large acquisitions, often targeting Phase 3+ assets for near-term revenue, while Lilly, Novo Nordisk, and J&J focus on smaller, earlier-stage deals. AbbVie surprisingly sits between these extremes. Most >$1B deals involve Phase 3 assets. 🔥 Key therapeutic areas for M&A are oncology, I&I, CNS, rare diseases, and cardiovascular/metabolic, with a growing focus on obesity treatments. Most deals are mid-sized ($1-5B), and after mega-deals, companies reduce activity to focus on integration. 👉 In 2024, deal flow is around $30B, well below 2023’s $110B and 2022’s $66B, but deal count remains above historical averages, reflecting fewer large transactions. Source: Kudos to Andrew Pannu and Sleuth Insights for their incredible work. #pharma #biotech #biopharma

The pace of biotech innovation can be daunting, but we’re here to help you navigate this exciting landscape! But here’s the good news: We're actively providing the resources you need to stay informed and connected. Our FREE Newsletter is your gateway to the latest breakthroughs, ensuring you're never left behind. Here’s the proof: 90% of our subscribers report feeling more informed about biotech developments. Join a community of over 10,000 biotech enthusiasts who share insights and updates weekly! Join here: https://lnkd.in/decTJM6Q 🔔 Stay at the Forefront with critical updates and insider insights. 🔥 Don’t Miss a Beat in the rapidly evolving world of biotech! 👉 Click Here Join Now and transform your understanding of biotech today! #Biotech #Biopharma #Pharmaceuticals

Top Pharma Companies by 2024 Pipeline Size 🧬 Check out the latest data from the Citeline Pharma R&D Review 2024, showcasing the top global pharmaceutical companies ranked by the number of drug candidates in their pipeline. 🏆 🔹 Roche leads the pack with 218 drug candidates, followed closely by Pfizer at 205. 🔹 AstraZeneca, Lilly, and Bristol Myers Squibb round out the top five, all with impressive R&D pipelines. 🔹 Companies from the USA, Switzerland, France, UK, China, and Japan are all represented, highlighting the global nature of pharmaceutical innovation. Key insights: The USA dominates the list, with several companies leading innovation. Switzerland’s Roche holds the top position, demonstrating its continued investment in cutting-edge research. AstraZeneca and GSK represent the UK, showcasing the country's strong role in pharma R&D. China's presence with Hengrui signals growing innovation power in Asia. 🌐 The future of healthcare innovation looks brighter than ever as these companies work tirelessly on new treatments for various diseases. #biotech #biopharma #pharma

𝐑𝐚𝐝𝐢𝐨𝐩𝐡𝐚𝐫𝐦𝐚 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞 🧪 38 companies below encompassing 45 clinical stage programs, including: 8 Phase III; 9 Phase II; 28 Phase I/II programs. 👉 𝘋𝘪𝘥 𝘺𝘰𝘶 𝘬𝘯𝘰𝘸? ITM Radiopharm raised €188 million ($204 million) last week in a funding round that will largely be used to advance and expand the Munich company’s radiopharmaceutical pipeline. The funds, which come a year after ITM raised €255 million, are a 𝐬𝐢𝐠𝐧 𝐨𝐟 𝐠𝐫𝐨𝐰𝐢𝐧𝐠 𝐢𝐧𝐯𝐞𝐬𝐭𝐨𝐫 𝐢𝐧𝐭𝐞𝐫𝐞𝐬𝐭 in the company’s products and the radio pharma market. Wow, strong resurgence! Source: Oppenheimer & Co Research. Kudos! #oncology #radiopharma #biotech #biopharma

Key upcoming catalysts in RNA medicine are driving innovation and breakthroughs in treating AATD, FCS, obesity, and cardiovascular diseases. Highlighted companies like Wave Life Sciences, Korro Bio, Ionis Pharmaceuticals, Arrowhead, and ProQR Therapeutics are leading programs in RNA editing, siRNA, and ASO technologies. Major milestones to watch include: 🔹 IND submissions, Phase 1/2 initiations, and PDUFA dates. 🔹 Critical Phase 3 data releases projected between 2024 and 2026. The RNA space remains a game-changer, offering hope for unmet medical needs and shaping the future of medicine. What are your thoughts on these key catalysts and RNA technology? #rna #biotech #biopharma #pharmaceuticals

𝐊𝐞𝐲 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐢𝐞𝐬 𝐚𝐧𝐝 𝐓𝐢𝐦𝐞𝐥𝐢𝐧𝐞 𝐨𝐟 𝐍𝐊 𝐂𝐞𝐥𝐥𝐬 Over the past 50 years, NK (Natural Killer) cells have transformed from a scientific curiosity to a powerful tool in cancer treatment, and infectious disease research. This timeline captures the key milestones and breakthroughs: • 1975: NK cells identified and their cytolytic activity reported. • 1990s-2000s: Key discoveries like NK receptors (KIRs, NKG2D) and their role in “missing self” recognition. • 2010s: CAR-NK therapy emerges as a novel immunotherapy for cancers. • 2020s: NK cells’ role in COVID-19 and the identification of new NK subsets and progenitors. From pioneering discoveries in NK biology to clinical trials for CAR-NK cells, this progress highlights both the power of collaboration and the immense potential of NK cells to revolutionize medicine. #immunotherapy #celltherapy #oncology #biotech

Stay ahead of the biotech curve this week with our FREE Newsletter: Your gateway to the latest breakthroughs, ensuring you're never left behind. Here’s the proof: 90% of our subscribers report feeling more informed about biotech developments. Join a community of over 10,000 biotech enthusiasts who share insights and updates weekly! Join here: https://lnkd.in/decTJM6Q 🔔 Stay at the Forefront with critical updates and insider insights. 🔥 Don’t Miss a Beat in the rapidly evolving world of biotech! 👉 Click Here Join Now and transform your understanding of biotech today! #Biotech #Biopharma #Pharmaceuticals

🚨 Exciting Announcement! 🚨 Our friends at SciRank have just launched an incredible new product to complement their comprehensive database of CDMOs and CRO reviews: the Biotech Startup Pack! If you're part of a biotech company searching for the perfect contract partner to bring your product to the clinic, this resource is a game-changer. Don't miss out—check them out today! #Biotech #LifeSciences #StartupResources

Companies Focused on Neuroinflammatory Targets 👇 72 biopharmaceutical companies below categorised by Preclinical to Phase III and based in therapeutic areas such as CNS, Gene Therapy and iPSCs. - NLPR 3 - PGRN - TREM2 - Other #neurology #biotech #genetherapy #biopharma

Quarterly Pharma Analysis: Top-Selling Medicines 👇 Strong Performers: Mounjaro (Lilly): Achieved $12B annualized sales in just 9 quarters post-FDA approval (May 2022), outpacing Ozempic’s 6-year journey to the same milestone. Public awareness driven by Ozempic’s success, combined with recent data favoring tirzepatide, positions Mounjaro for accelerated growth. Dupixent (Regeneron/Sanofi): Surpassed $15B in annualized sales, driven by new indications and 1M patients worldwide. Recent FDA/EMA approval for COPD expands its reach as the first biologic for the condition. Challenged Performers: Vaccines: Gardasil (Merck): Sales fell 11% YoY due to inventory destocking and weaker demand in China. Shingrix (GSK): China-related weakness prompted a downward forecast revision. 2024 LOEs: Stelara (J&J): Faces biosimilar competition. Eylea (Regeneron): Amgen’s biosimilar Pavblu launching soon after a court ruling declined Regeneron’s injunction request. Key Takeaway: While blockbusters like Mounjaro and Dupixent continue to soar, vaccines and LOE-prone therapies highlight the challenges of competition and market shifts in pharma’s dynamic landscape. Source: Maven Bio - great insights page and company. Follow them! #biotech #obesity #biopharma #pharma